178 related articles for article (PubMed ID: 24937521)
1. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
Datta J; Vollmer CM
South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
3. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
4. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
5. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
Cancer Sci; 2011 Sep; 102(9):1673-9. PubMed ID: 21615621
[TBL] [Abstract][Full Text] [Related]
7. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma.
Giovinazzo F; Turri G; Zanini S; Butturini G; Scarpa A; Bassi C
Surg Oncol; 2012 Dec; 21(4):e171-82. PubMed ID: 22981281
[TBL] [Abstract][Full Text] [Related]
9. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y; Holmes MV; Chen Z; Kartsonaki C
J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers in pancreatic cancer diagnosis.
Herreros-Villanueva M; Gironella M; Castells A; Bujanda L
Clin Chim Acta; 2013 Mar; 418():22-9. PubMed ID: 23305796
[TBL] [Abstract][Full Text] [Related]
11. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
[TBL] [Abstract][Full Text] [Related]
12. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
Partensky C
Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
[TBL] [Abstract][Full Text] [Related]
13. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
14. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
15. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
[TBL] [Abstract][Full Text] [Related]
16. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
Chang JC; Kundranda M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
[TBL] [Abstract][Full Text] [Related]
17. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
18. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
19. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
[TBL] [Abstract][Full Text] [Related]
20. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.
Sahni S; Krisp C; Molloy MP; Nahm C; Maloney S; Gillson J; Gill AJ; Samra J; Mittal A
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129682. PubMed ID: 32663515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
